InsiderTrades.com logo
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
From Priority Gold   |   Ad
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Click here for your free guide

Douglas Snyder Biography and Net Worth

Insider of GW Pharmaceuticals
  • Phone
  • Email
  • Website


Douglas Snyder serves as Chief Legal Officer of the Company. Mr. Snyder brings more than 20 years of experience providing counsel in the pharmaceutical industry, at the U.S. Food and Drug Administration (“FDA”) and in private practice. Prior to joining the Company, he led the legal and compliance teams as senior vice president, general counsel, and secretary for Actelion U.S., a pharmaceuticals and biotechnology company. Prior to that, Mr. Snyder held the position of senior vice president, general counsel, secretary at Eisai Inc., a pharmaceutical subsidiary of a research-based human health care company, where he led the Legal, Compliance, Legislative Affairs, Internal Audit and Security Group. From 1999-2005, he was vice-president, associate general counsel for GlaxoSmithKline (“GSK”). During his tenure at GSK, Mr. Snyder managed the legal and communications strategies related to some of GSK’s most high-profile matters concerning the New York Attorney General, the U.S. Department of Justice and the FDA. Before joining the pharmaceutical industry, he held the role of Associate General Counsel for the FDA where he counseled the Commissioner, appeared before Congress in key initiatives, and led the initial False Claims/Kickback cases against the pharmaceutical industry.

What is Douglas B. Snyder's net worth?

The estimated net worth of Douglas B. Snyder is at least $13.54 million as of March 26th, 2021. Mr. Snyder owns 61,848 shares of GW Pharmaceuticals stock worth more than $13,542,238 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Snyder may own. Additionally, Mr. Snyder receives an annual salary of $787,020.00 as Insider at GW Pharmaceuticals. Learn More about Douglas B. Snyder's net worth.

How old is Douglas B. Snyder?

Mr. Snyder is currently 57 years old. There are 4 older executives and no younger executives at GW Pharmaceuticals. Learn More on Douglas B. Snyder's age.

What is Douglas B. Snyder's salary?

As the Insider of GW Pharmaceuticals plc, Mr. Snyder earns $787,020.00 per year. There are 2 executives that earn more than Mr. Snyder. The highest earning executive at GW Pharmaceuticals is Mr. Justin D. Gover, CEO & Exec. Director, who commands a salary of $1,190,000.00 per year. Learn More on Douglas B. Snyder's salary.

How do I contact Douglas B. Snyder?

The corporate mailing address for Mr. Snyder and other GW Pharmaceuticals executives is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. GW Pharmaceuticals can also be reached via phone at 44-12-2326-6800 and via email at [email protected]. Learn More on Douglas B. Snyder's contact information.

Has Douglas B. Snyder been buying or selling shares of GW Pharmaceuticals?

Douglas B. Snyder has not been actively trading shares of GW Pharmaceuticals during the past quarter. Most recently, Douglas B. Snyder sold 8,400 shares of the business's stock in a transaction on Friday, March 26th. The shares were sold at an average price of $18.12, for a transaction totalling $152,208.00. Following the completion of the sale, the insider now directly owns 61,848 shares of the company's stock, valued at $1,120,685.76. Learn More on Douglas B. Snyder's trading history.

Who are GW Pharmaceuticals' active insiders?

GW Pharmaceuticals' insider roster includes Cabot Brown (Director), Adam George (Insider), Justin Gover (CEO), Geoffrey Guy (Chairman), Volker Knappertz (Director), Douglas Snyder (Insider), and Christopher Tovey (COO). Learn More on GW Pharmaceuticals' active insiders.

Douglas B. Snyder Insider Trading History at GW Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2021Sell8,400$18.12$152,208.0061,848View SEC Filing Icon  
12/7/2020Sell26,904$11.01$296,213.0422,104View SEC Filing Icon  
9/30/2020Sell14,400$8.13$117,072.0026,904View SEC Filing Icon  
8/11/2020Sell24,000$9.40$225,600.00122,364View SEC Filing Icon  
7/6/2020Sell9,804$10.50$102,942.00View SEC Filing Icon  
2/26/2020Sell3,876$9.17$35,542.9270,104View SEC Filing Icon  
8/19/2019Sell5,424$13.04$70,728.9673,740View SEC Filing Icon  
8/12/2019Sell3,756$13.88$52,133.2879,164View SEC Filing Icon  
7/9/2019Sell4,968$14.42$71,638.56View SEC Filing Icon  
See Full Table

Douglas B. Snyder Buying and Selling Activity at GW Pharmaceuticals

This chart shows Douglas B Snyder's buying and selling at GW Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

GW Pharmaceuticals Company Overview

GW Pharmaceuticals logo
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $218.96
Low: $218.96
High: $218.96

50 Day Range

MA: $218.59
Low: $216.90
High: $219.28

2 Week Range

Now: $218.96
Low: $87.07
High: $219.57

Volume

N/A

Average Volume

899,771 shs

Market Capitalization

$6.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
From Priority Gold   |   Ad
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Click here for your free guide